XTL Biopharmaceuticals Ltd. (XTLB) Stock Score, Valuation & Financial Research

XTL Biopharmaceuticals Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for XTLB

XTL Biopharmaceuticals Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 2.02. These figures are a research snapshot, not a buy or sell recommendation.

What XTL Biopharmaceuticals Ltd. does

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet medical needs. The company operates as a holding company that seeks to advance clinical-stage assets through development pipelines, relying on external partnerships and contract research organizations for operational execution.

Products and services

  • The company is engaged in the development of therapeutic candidates, including hCDR1 for the treatment of systemic lupus erythematosus and other autoimmune diseases.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and development activities. Source

Business strengths to evaluate

  • Focus on clinical-stage assets with potential for high unmet medical need Source

Business risks and research considerations

  • History of operating losses and uncertainty regarding future profitability Source
  • Dependence on third-party service providers and clinical trial outcomes Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

XTLB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.02
Market capitalization:
1.91M (currency not supplied)
Revenue:
USD 451K
Net income:
USD -1.03M
Free cash flow:
USD -1.03M
Cash:
USD 76K
Total debt:
USD 269K
EPS:
USD -2.88

What stands out

  • Free cash flow is USD -1.03M, negative for the stored period.
  • The balance sheet shows USD 76K of cash versus USD 269K of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -227.3% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -227.7% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 193K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for XTLB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can XTLB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is XTLB's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for XTLB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of XTLB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research XTLB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.